Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index.
See the complete event guide here.
Here’s a snapshot of our speaker faculty, including expert industry leaders such as:
- Sayumi Yamazoe, Senior Principal Scientist, Bristol Myers Squibb
- Romas Kudirka, Director, Chemistry & Bioconjugation, Bolt Biotherapeutics
- Donglu Zhang, Senior Fellow, Genentech
- Paul Song, Chief Scientific Officer, Genequantum
- Patrick Higgs, Principal Scientist, Chemistry, Iksuda
- Noah Bindman, Principal Scientist, Seagen
- Marc-André Kasper, Director, Chemistry & Early Discovery, Tubulis
- Paul Sauter, Director, Chemistry, VERAXA
…and many more!
Find the full list of speakers and session details here.
Be part of the first industry-dedicated meeting for professionals just like you, interested in learning about developments in the field of ADC linkers and conjugations, and overcoming common challenges with stability.